US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026

1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal 
Patch

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. US Transdermal Patch Market Overview
6.1 Current Market Scenario
6.2 US Transdermal Patch Clinical Pipeline Overview
6.2.1 By Company 
6.2.2 By Drug Class 
6.2.3 By Indication 
6.2.4 By Phase 

7. Generic & Branded Transdermal Patches

8. Value Chain Analysis for Transdermal Patch Market
8.1 Research & Development
8.2 Manufacturing
8.3 Marketing & Distribution
8.4 Price to End User

9. US Transdermal Patch Contract Manufacturing Organization (CMO)

10. Transdermal Patches for Cardiovascular Diseases - US Market Availability, Dosage & Price Analysis
10.1 Clonidine Transdermal Patch (Catapres-TTS)
10.2 Nitro Glycerin Transdermal Patch
10.2.1 Nitro-Dur
10.2.2 Nitro TD Patch A
10.2.3 Generic Nitroglycerine Transdermal Patch

11. Opioid Drug Containing Transdermal Patches - US Market Availability, Dosage & Price Analysis
11.1 Fentanyl Transdermal Patch (Duragesic)
11.2 Buprenorphine Transdermal Patch (Butrans Patch)

12. Transdermal Patches for Neurological Disorders - US Market Availability, Dosage & Price Analysis
12.1 Selegiline Transdermal Patch (Emsam)
12.2 Scopolamine Transdermal Patch (Transderm-Scop)
12.3 Rivastigmine Transdermal Patch (Exelon)
12.4 Methylphenidate Transdermal Patch (Daytrana)
12.5 Asenapine Transdermal Patch (Secuado)
12.6 Rotigotine Transdermal Patch (Neupro)

13. Transdermal Patch in Hormonal Therapy - US Market Availability, Dosage & Price Analysis
13.1 Estradiol Transdermal Patch
13.1.1 Alora
13.1.2 Vivelle-Dot
13.1.3 Minivelle
13.1.4 Climara
13.1.5 Generic Estradiol Transdermal Patch
13.2 Testosterone Transdermal Patch (Androderm)
13.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch
13.3.1 Xulane
13.3.2 Combipatch
13.4 Estradiol/Levonorgestrel Transdermal Patch (Climara Pro)
13.5 Ethinyl Estradiol/Levonorgestrel (Twirla)

14. Transdermal Patches for Other Conditions - US Market Availability, Dosage & Price Analysis
14.1 Nicotine Transdermal Patch (Nicoderm CQ/Harbitrol)
14.2 Oxybutynin Transdermal Patch (Oxytrol)
14.3 Sancuso (Granisetron)

15. US - Transdermal Patch Clinical Pipeline By Company, Indication & Phase
15.1 Research
15.2 Preclinical
15.3 Clinical
15.4 Phase-I
15.5 Phase-I/II
15.6 Phase-II
15.7 Phase-III
15.8 Preregistration
15.9 Registered

16. US - Marketed Transdermal Patch Clinical Insight by Company & Indication

17. US Transdermal Patch Market Opportunity Assessment
17.1 Parkinson’s Disease
17.2 Alzheimer's Disease
17.3 Female Contraceptive
17.4 Nicotine Replacement Therapy
17.5 Cardiovascular Disease
17.6 Insulin
17.7 Vaccine

18. US Transdermal Patch Market Dynamics
18.1 Favorable Market Parameters
18.2 Commercialization Challenges

19. US Transdermal Patch Market Future Prospects

20. Competitive Landscape
20.1 3M Pharmaceuticals
20.2 Acrux
20.3 Agile Therapeutics
20.4 Allergan
20.5 ANI Pharmaceuticals
20.6 Antares Pharma
20.7 Bayer HealthCare Pharmaceuticals
20.8 Corium International
20.9 Chase Pharmaceuticals
20.10 DURECT Corporation
20.11 Endo Pharmaceuticals
20.12 Fempharm
20.13 Hisamitsu Pharmaceutical
20.14 Immune Pharmaceuticals
20.15 Imprimis Pharmaceuticals
20.16 Ipsen Bioscience
20.17 Johnson & Johnson
20.18 LaSalle Laboratories
20.19 Lavipharm-increase
20.20 MINRAD International
20.21 NeurogesX
20.22 Noven Pharmaceuticals
20.23 NuPathe
20.24 Nuvo Research
20.25 Novartis
20.26 Pain Therapeutics
20.27 ProStrakan
20.28 Purdue Pharma
20.29 Sanofi
20.30 Scilex Pharmaceuticals
20.31 Senju Pharmaceutical
20.32 Somerset Pharmaceuticals
20.33 Teikoku Seiyaku
20.34 Therapeutic Discovery Corporation
20.35 Transdermal Delivery Solutions Corp
20.36 UCB-full form
20.37 Xel Pharmaceuticals
20.38 Zosano Pharma

List of Tables
Table 2-1: Differences between Active & Passive Transdermal Patches
Table 4-1: Transdermal Patches for Various Disease Indications
Table 6-1: Features Required in Transdermal Patches
Table 6-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 7-1: Similarities & Difference Between Generic & Branded Transdermal Patches
Table 7-2: US - Some Generic Transdermal Patches Available in Market
Table 8-1: Breakdown of Transdermal Patch Value Chain Analysis
Table 11-1: Duragesic - Initial Dose Conversion from Other Opioids
Table 11-2: Butrans - Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 12-1: Daytrana - Dose Increment Pattern for Treatment of ADHD
Table 17-1: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2021-2026
Table 17-2: Description of Neupro Patch for Parkinson’s Disease
Table 17-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2021-2026
Table 17-4: Transdermal Patches for Alzheimer’s Disease
Table 17-5: Description of Ortho Evra Contraceptive Patch
Table 17-6: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 17-7: Clonidine Patch - Difference Between Generic & Branded Transdermal Patch
Table 17-8: US - Estimated Adoption Rates for Hypertension Transdermal Patches, 2021-2026
Table 17-9: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2021-2026
Table 17-10: US - Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2021-2026
Table 20-1: Pain Therapeutics Clinical Pipeline

List of Figures
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 4-1: Properties of Transdermal Therapeutics
Figure 4-2: Components of Transdermal Patch
Figure 4-3: Types of Permeation Enhancers
Figure 4-4: Schematic Representation of Iontophoresis
Figure 4-5: Mechanism of Scopolamine Transdermal Patch
Figure 4-6: Mechanism of Nicotine Transdermal Patch
Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 5-1: Issues with Traditional Drug Delivery Methods
Figure 5-2: Advantages of Transdermal Patch
Figure 5-3: Consistent Drug Supply by Transdermal Patch
Figure 6-1: Advantages of Transdermal Patches
Figure 6-2: Disadvantages of Transdermal Patches
Figure 6-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 6-4: US - Transdermal Patch Market (US$ Billion), 2020 - 2026
Figure 6-5: US Transdermal Patch Pipeline by Company (Numbers), 2021 till 2026
Figure 6-6: US Transdermal Patch Pipeline by Drug Class (Numbers), 2021 till 2026
Figure 6-7: US Transdermal Patch Pipeline by Indication (Numbers), 2021 till 2026
Figure 6-8: US - Transdermal Patch Pipeline by Phase (%),2021 till 2026
Figure 6-9: US Transdermal Patch Pipeline by Phase (Numbers), 2021 till 2026
Figure 7-1: Requirement in Generic Transdermal Patches
Figure 7-2: Reservations for Generic Transdermal Patches
Figure 7-3: US - Estimated Cost Comparison of Branded vs. Generic Contraceptive Patch
Figure 7-4: US - Estimated Cost Comparison of Cigarettes, Generic & Branded Nicotine Patches
Figure 8-1: Basic Features of Transdermal Patch Value Chain
Figure 8-2: Steps Involved in Transdermal Patch Manufacturing
Figure 9-1: Stages of Transdermal Patch Development
Figure 9-2: Advantages of Using Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 9-3: Requirements from Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 10-1: Catapres-TTS - FDA Approval & First Generic Approval Year
Figure 10-2: Catapres-TTS - Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), March’2021
Figure 10-3: Catapres-TTS - Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), March’2021
Figure 10-4: Catapres-TTS - Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), March’2021
Figure 10-5: Generic Clonidine Patch - Price for 4 Transdermal Film & Price Per Unit of 0.1mg Transdermal Film (US$), March’2021
Figure 10-6: Generic Clonidine Patch - Price for 4 Transdermal Film & Price Per Unit of 0.2mg Transdermal Film (US$), March’2021
Figure 10-7: Generic Clonidine Patch - Price for 4 Transdermal Film & Price Per Unit of 0.3mg Transdermal Film (US$), March’2021
Figure 10-8: Catapres-TTS - Recommended Initial & Incremented Dose (mg/Week)
Figure 10-9: Catapres-TTS - Monthly & Annual Treatment Cost using 0.1mg Dose (US$), March’2021
Figure 10-10: Nitro-Dur - Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), March’2021
Figure 10-11: Nitro-Dur - Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), March’2021
Figure 10-12: Nitro-Dur - Price for 30 Films Supply & Price Per Unit of 0.3mg Film (US$), March’2021
Figure 10-13: Nitro-Dur - Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), March’2021
Figure 10-14: Nitro-Dur - Price for 30 Films Supply & Price Per Unit of 0.6mg Film (US$), March’2021
Figure 10-15: Nitro-Dur - Price for 30 Films Supply & Price Per Unit of 0.8mg Film (US$), March’2021
Figure 10-16: Nitro TD Patch A - Price for 30 Patch supply & Price Per Unit (US$), March’2021
Figure 10-17: Generic Nitroglycering Transdermal Patch - Price for 30 Films Supply & Price Per Unit of 0.1mg Film (US$), March’2021
Figure 10-18: Generic Nitroglycering Transdermal Patch - Price for 30 Films Supply & Price Per Unit of 0.2mg Film (US$), March’2021
Figure 10-19: Generic Nitroglycering Transdermal Patch - Price for 30 Films Supply & Price Per Unit of 0.4mg Film (US$), March’2021
Figure 10-20: Generic Nitroglycering Transdermal Patch - Price for 30 Films Supply & Price Per Unit of 0.6 mg Film (US$), March’2021
Figure 11-1: Duragesic - FDA Approval Year by Dose
Figure 11-2: Duragesic - First Generic Approval Year by Dose
Figure 11-3: Duragesic - Price for 5 Patch Supply of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), March’2021
Figure 11-4: Duragesic - Price per Unit of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), March’2021
Figure 11-5: Generic Fentanyl Transdermal Patch - Price for 5 Patch Supply of Various Doses (US$), March’2021
Figure 11-6: Generic Fentanyl Transdermal Patch - Price per Unit of Various Doses (US$), March’2021
Figure 11-7: Butrans - FDA Approval Year by Dose
Figure 11-8: Butrans - Price for 4 Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), March’2021
Figure 11-9: Butrans - Price per Unit of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), March’2021
Figure 11-10: Generic Buprenorphine Transdermal Patch - Price for 4 Patch supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), March’2021
Figure 12-1: Emsam - Price for 30 Patch Supply & Price Per Unit of Various Doses of Emsam Transdermal Patches (US$), March’2021
Figure 12-2: Emsam - Monthly & Annual Treatment Cost of Parkinson’s Disease (US$), March’2021
Figure 12-3: Transderm-Scop - Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US$), March’2021
Figure 12-4: Transderm-Scop - Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US$), March’2021
Figure 12-5: Generic Scopolamine Transdermal Patch - Price for a Supply of 4, 10 & 24 Patches of 1mg Transdermal Film (US$), March’2021
Figure 12-6: Exelon - Price for 30 Transdermal Patch Supply of Exelon (US$), March’2021
Figure 12-7: Generic Rivastigmine Transdermal Patch - Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), March’2021
Figure 12-8: Exelon - Initial & Maintenance Dose for the Treatment of Parkinson’s disease
Figure 12-9: Exelon - Monthly & Annual Treatment Cost for Treatment of Parkinson’s Disease (US$), March’2021
Figure 12-10: Daytrana - Patent Issue & Expiration Year
Figure 12-11: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), March’2021
Figure 12-12: Secuado - Patent Issue & Expiration Year
Figure 12-13: Secuado - Price for 30 Transdermal Film & Price Per Unit of Various Dose Regimens (US$), March’2021
Figure 12-14: Secuado - Recommended Initial & Incremented Dose (mg/Day)
Figure 12-15: US - Aderis Pharma’s Neupro Patent Issue & Expiration Year
Figure 12-16: US - UCB’s Neupro Patent Issue & Expiration Year
Figure 12-17; Neupro - Price for Supply of 30 Transdermal Films & Price Per Unit (US$), March’2021
Figure 12-18: Neupro - Initial & Maximum Recommended Dose for Early Stage Parkinson (mg/day)
Figure 12-19: Neupro - Initial & Maximum Recommended Dose for Late Stage Parkinson (mg/day), March’2021
Figure 12-20: Global - Neupro Sales (US$ Million), 2017 - 2020
Figure 12-21: US - Neupro Sales (US$ Million), 2018 - 2020
Figure 12-22: Global - Neupro Sales by Region (US$ Million), 2020
Figure 12-23: Global - Neupro Sales by Region (US$ Million), 2020
Figure 13-1: Alora - FDA Approval Year by Dose
Figure 13-2: Alora - Price for a Supply of 8 Patches of Dose 0.025mg, 0.05mg, 0.075mg & 0.1mg (US$), March’2021
Figure 13-3: Alora - Price per Unit of 0.025mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch(US$), March’2021
Figure 13-4: Alora - Recommended Dose for Treatment of vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice in a Week), March’2021
Figure 13-5: Vivelle-Dot - FDA Approval & First Generic Approval Year
Figure 13-6: Vivelle-Dot - Price for a Supply of 24 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US$), March’2021
Figure 13-7: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US$), March’2021
Figure 13-8: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day Twice a Week), March’2021
Figure 13-9: Minivelle - FDA Approval Year by Dose
Figure 13-10: Minivelle - FDA Approval & First Generic Approval Year
Figure 13-11: US - Minivelle Patent Issue & Expiration Year
Figure 13-12: Minnivelle - Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), March’2021
Figure 13-13: Minivelle - Recommended Dose by Indication (mg/Day), March’2021
Figure 13-14: Climara - FDA Approval Year by Dose
Figure 13-15: Climara - FDA Approval & First Generic Approval Year
Figure 13-16: Climara - Average Price for a Supply of 4 Transdermal Films & Price Per Unit of Various Doses (US$), March’2021
Figure 13-17: Generic Estradiol Transdermal Patch - Price for 4 Films Supply & Price Per Unit of 0.025mg Film (US$), March’2021
Figure 13-18: Generic Estradiol Transdermal Patch - Price for 4 Films Supply & Price Per Unit of 0.0375mg Film (US$), March’2021
Figure 13-19: Generic Estradiol Transdermal Patch - Price for 4 Films Supply & Price Per Unit of 0.05mg & 0.06mg Dose (US$), March’2021
Figure 13-20: Generic Estradiol Transdermal Patch - Price for 4 Films Supply & Price Per Unit of 0.075mg Film (US$), March’2021
Figure 13-21: Generic Estradiol Transdermal Patch - Price for 4 Films Supply & Price Per Unit of 0.1mg Film (US$), March’2021
Figure 13-22: Androderm - Price for 60 Films Supply & per Unit Price of 2mg Transdermal Films (US$), March’2021
Figure 13-23: Androderm - Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US$), March’2021
Figure 13-24: Androderm - Recommended Initial & Maintainence Dose fot Treatment of Hypogonadism (mg/day), March’2021
Figure 13-25: Ortho Evara - FDA approval & Withdrawal Year
Figure 13-26: Xulane - FDA Approval & First Generic Approval Year
Figure 13-27: Xulane - Price for a Supply of 3 Patches & Price Per Unit of 35mcg-150mcg Transdermal Patch (US$), March’2021
Figure 13-28: Xulane - Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 13-29: CombiPatch - Price for a Supply of 8 Patches & Price Per Unit of Various Doses (US$), March’2021
Figure 13-30: Climara Pro - Price for a Supply of 4 Films & Price Per Unit of Transdermal Film (US$), March’2021
Figure 13-31: US - Twirla Patent Issue & Expiration Year
Figure 13-32: Twirla - Price for a Supply of 3 Patches & Price Per Unit of 30mcg-120mcg Transdermal Patch (US$), March’2021
Figure 13-33: Twirla - Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 14-1: Nicotine Transdermal Patch - FDA Approval Year by Product
Figure 14-2: Nicoderm CQ - Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 14-3: Nicoderm CQ - Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US$), March’2021
Figure 14-4: Harbitrol - Price for a Supply of 28 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 14-5: Generic Nicotine Patch - Price for a Supply of 7 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 14-6: Generic Nicotine Patch - Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), March’2021
Figure 14-7: Generic Nicotine Patch - Price for a Supply of 28 Transdermal Patches of Doses 14mg & 21mg (US$), March’2021
Figure 14-8: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 14-9: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)
Figure 14-10: Nicoderm CQ - Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes & More than 10 Cigarettes (US$), March’2021
Figure 14-11: Oxytrol - Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), March’2021
Figure 14-12: Oxytrol For Women - Price of 4 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), March’2021
Figure 14-13: Oxytrol For Women - Price of 8 Patch Supply & Price Per Unit of 3.9mg Transdermal Patch (US$), March’2021
Figure 14-14: Sancuso - Patent Issue & Expiration Year
Figure 17-1: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 17-2: US - Susceptibility of Parkinson Disease Among Males and Females
Figure 17-3: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 17-4: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 17-5: US - Parkinson’s Disease Incidences, 2020-2026
Figure 17-6: US - Estimated Sales of Neupro Patch (US$ Million), 2020-2026
Figure 17-7: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2021
Figure 17-8: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2021
Figure 17-9: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2021
Figure 17-10: US - Estimated Increase in Alzheimer’s Incidences (Million), 2020, 2030, 2040 & 2050
Figure 17-11: US - Estimated Incidences of Alzheimer’s Disease, 2021-2026
Figure 17-12: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 17-13: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 17-14: US - Decrease in Number of Smokers due to Nicotine Patch, 2005, 2013 & 2019
Figure 17-15: US - Prevalence of Smokers by Gender (%), 2019
Figure 17-16: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 17-17: US - Estimated Cases of Adult Hypertension (Million), 2019, 2025 & 2030
Figure 17-18: US - Adult Hypertension Cases by Gender (Million), 2019
Figure 17-19: US - Adult Hypertension Cases by Gender (Million), 2019
Figure 17-20: US - Adult Hypertension Cases by Age (Million), 2019
Figure 17-21: US - Hypertension Prevalence Rate by Age (%), 2019
Figure 17-22: US - Hypertension Incidences (Million), 2020-2026
Figure 17-23: Rank of US among Different Diabetes Prone Countries
Figure 17-24: US - Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
Figure 17-25: US - Undiagnosed & Diagnosed Diabetic Population (Million), 2019
Figure 17-26: US - Undiagnosed & Diagnosed Diabetic Population (%), 2019
Figure 17-27: US - Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
Figure 17-28: US - Estimated Diabetic Population (Million), 2020-2026
Figure 17-29: Benefits of Insulin Transdermal Patch
Figure 17-30: Drawback of Insulin Transdermal Patch
Figure 17-31: Benefits of Vaccine Transdermal Patch
Figure 17-32: Drawbacks of Vaccine Transdermal Patch
Figure 17-33: US - Number of HIV Cases (Million), 2012, 2014 & 2018
Figure 17-34: US - Estimated Number of HIV Cases (Million), 2020, 2025 & 2030
Figure 17-35: US - Estimated HIV Incidences, 2020-2026
Figure 18-1: Transdermal Patch Market Favorable Factors
Figure 18-2: Transdermal Patch Market Commercialization Challenges
Figure 20-1: Acrux Clinical Pipeline
Figure 20-2: Agile Therapeutics Clinical Pipeline
Figure 20-3: Antares Pharma Clinical Pipeline
Figure 20-4: Corium International Clinical Pipeline
Figure 20-5: Durect Corporation Clinical Pipeline
Figure 20-6: Endo Pharmaceuticals Clinical Pipeline
Figure 20-7: Immune Pharmaceuticals Clinical Pipeline
Figure 20-8: Novartis Clinical Pipeline
Figure 20-9: Senju Pharmaceuticals Clinical Pipeline
Figure 20-10: Xel Pharmaceuticals Clinical Pipeline
Figure 20-11: Zosano Pharma Clinical Pipeline